These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25468795)

  • 1. In vitro evaluation of synergistic activity between ciprofloxacin and broad snouted caiman serum against Escherichia coli.
    Siroski PA; Russi NB; Ortega HH; Formentini EA
    Res Vet Sci; 2015 Feb; 98():98-105. PubMed ID: 25468795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model.
    Jakobsen L; Cattoir V; Jensen KS; Hammerum AM; Nordmann P; Frimodt-Møller N
    J Antimicrob Chemother; 2012 Oct; 67(10):2438-44. PubMed ID: 22685162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
    Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
    Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates.
    Liu X; Lazzaroni C; Aly SA; Thungrat K; Boothe DM
    Vet Microbiol; 2014 Dec; 174(3-4):514-522. PubMed ID: 25465666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae.
    So W; Crandon JL; Nicolau DP
    J Urol; 2015 Aug; 194(2):563-70. PubMed ID: 25637857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.
    Gebru E; Damte D; Choi MJ; Lee SJ; Kim YH; Park SC
    Vet Microbiol; 2012 Jan; 154(3-4):384-94. PubMed ID: 21893387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Composition of the outer membrane proteins of Escherichia coli strains in relation to serum susceptibility after exposure to subinhibitory concentrations of amikacin and ciprofloxacin.
    Wojnicz D; Cisowska A
    Int J Antimicrob Agents; 2009 Jun; 33(6):579-82. PubMed ID: 19232480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxicity of commercial-mixed glyphosate in broad snouted caiman (Caiman latirostris).
    Siroski PA; Poletta GL; Latorre MA; Merchant ME; Ortega HH; Mudry MD
    Chem Biol Interact; 2016 Jan; 244():64-70. PubMed ID: 26658029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131.
    Johnson JR; Porter SB; Thuras P; Johnson TJ; Price LB; Tchesnokova V; Sokurenko EV
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7132-5. PubMed ID: 26324269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofloxacin-resistant and extended-spectrum β-lactamase-producing Escherichia coli ST410 strain carrying the mcr-1 gene associated with bloodstream infection.
    Rocha IV; Andrade CADN; Campos TL; Rezende AM; Leal NC; Vidal CFL; Xavier DE
    Int J Antimicrob Agents; 2017 May; 49(5):655-656. PubMed ID: 28302539
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of sub-minimum inhibitory concentrations of ciprofloxacin on enteroaggregative Escherichia coli and the role of the surface protein dispersin.
    Mortensen NP; Fowlkes JD; Maggart M; Doktycz MJ; Nataro JP; Drusano G; Allison DP
    Int J Antimicrob Agents; 2011 Jul; 38(1):27-34. PubMed ID: 21570813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activity of gentamicin and ciprofloxacin against Gram-negative bacteria: interactions with pig and calf sera.
    Miglioli PA; Silini R; Carzeri O; Grabocka E; Allerberger F
    Pharmacol Res; 1999 Apr; 39(4):321-3. PubMed ID: 10208763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and simple determination of ciprofloxacin resistance in clinical strains of Escherichia coli.
    Santiso R; Tamayo M; Fernández JL; del Carmen Fernández M; Molina F; Villanueva R; Gosálvez J; Bou G
    J Clin Microbiol; 2009 Aug; 47(8):2593-5. PubMed ID: 19571026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.
    Khan DD; Lagerbäck P; Malmberg C; Kristoffersson AN; Wistrand-Yuen E; Sha C; Cars O; Andersson DI; Hughes D; Nielsen EI; Friberg LE
    Int J Antimicrob Agents; 2018 Mar; 51(3):399-406. PubMed ID: 29127049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttreatment changes in Escherichia coli antimicrobial susceptibility rates among diarrheic patients treated with ciprofloxacin.
    Putnam SD; Sanders JW; Tribble DR; Rockabrand DR; Riddle MS; Rozmajzl PJ; Frenck RW
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2571-2. PubMed ID: 15917577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
    Machuca J; Ortiz M; Recacha E; Díaz-De-Alba P; Docobo-Perez F; Rodríguez-Martínez JM; Pascual Á
    J Antimicrob Chemother; 2016 Nov; 71(11):3066-3071. PubMed ID: 27494906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates.
    Lin CY; Huang SH; Chen TC; Lu PL; Lin WR; Chen YH
    J Microbiol Immunol Infect; 2008 Aug; 41(4):325-31. PubMed ID: 18787740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.